Budigalimab (ABBV 181; PR 1648817) is a humanized PD-1) receptor. Budigalimab is Fc mutated thus to reduce Fc receptor interactions and limit effector function[1].
[1]. Powderly J, et al. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181). Clin Transl Sci. 2021 Jan;14(1):277-287.
















